Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

BSD Medical's Stock is Rising Fast: BSDM

|Includes: Perseon Corporation (PRSN)

BSD Medical is going up like hotcakes these days. I still think there is plenty of room for future growth. Today's trading is BSDM 3.16 +0.19 (6.40%) They recently had FDA approval for cancer treatment medical device. I don't think it's too late to get on board with this stock and see it as a real Long Term Growth Potential. They are selling their newly acquired 510K approved products at a rapid pace to Cancer Treatment centers across the country.

Wikinvest is a great Market Tool: BSD Medical




Texas Oncology Acquires Hyperthermia System from BSD Medical

SALT LAKE CITY, Sep 22, 2010 (BUSINESS WIRE) -- BSD Medical Corporation (BSDM 3.15, +0.18, +5.96%) announced today that Texas Oncology has acquired the BSD-500 Hyperthermia System (BSD-500). Texas Oncology is an affiliate of the United Network of US Oncology, the nation's largest network of community-based oncologists devoted to advancing cancer care and improving the cancer patient experience. The acquisition of the BSD-500 by Texas Oncology significantly increases the number of patients who will have access to hyperthermia treatment.

"We have known for years that hyperthermia was a promising treatment against cancer in the laboratory. Thanks to many dedicated scientists and clinicians, we now have very good clinical data and an excellent delivery device to offer our patients. Texas Oncology, along with US Oncology, is very excited to bring this technology to our patients and our network of doctors," said Barry N. Wilcox, MD, Chief of Radiation Oncology at Baylor University Medical Center and Texas Oncology physician.

Texas Oncology delivers high-quality cancer care with leading-edge technology and provides advanced treatment and therapy options to help patients in their fight against cancer. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with more than 300 physicians serving 100 sites of service throughout Texas and Southeastern New Mexico. Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Through its affiliation with US Oncology and the US Oncology Research network, Texas Oncology participates in innovative clinical trials from Phase I through Phase IV, and has played a role in the development of 42 Food and Drug Administration (FDA) approved cancer therapies.

The United Network of US Oncology is a nationwide physician network focused on advancing cancer care at the community level and on delivering the best cancer care for patients. US Oncology, and the more than one thousand physicians of the United Network of US Oncology, are committed to eradicating cancer through the collective use of their expertise, deep resources, and diverse cancer-fighting capabilities. With a focus on bringing patients world-class evidence-based treatments, the latest clinical trials in the community setting, and healthcare technology to enhance the overall patient experience, the United Network of US Oncology offers the vision and resources to help ensure the long-term success of community-based cancer care.

The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (NYSEARCA:PMA), which is the standard FDA approval required to market Class III medical devices in the United States, for the use of hyperthermia alone or in conjunction with radiation therapy for the treatment of certain tumors.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (NYSE:RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. BSD's hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD's microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company's products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

SOURCE: BSD Medical Corporation

BSD Medical Corporation
Dennis Gauger, 801-972-5555
Fax: 801-972-5930


BSD Medical Reports Publication of Article on BSD’s Pioneering Technology to Improve Heat Therapy

Business Wire  Sept 13, 2010

BSD Medical Corporation (NASDAQ:BSDM) (BSD or the Company) today reported publication of an article on BSD’s pioneering development of sophisticated technology to improve the delivery of heat therapy for the treatment of certain cancerous tumors. The article, “Interstitial microwave transition from hyperthermia to ablation: Historical perspectives and current trends in thermal therapy,” which was authored by TP Ryan, PF Turner, and B Hamilton, was published in the “International Journal of Hyperthermia,” the premier worldwide journal for original heat therapy research. PF Turner is BSD’s Chief Technology Officer and B Hamilton is one of BSD’s engineers. T Ryan is a leading researcher in heat therapy technology. BSD has been designing thermal therapy systems for 32 years and has obtained several pioneering patents for the devices, techniques, and methodology used in heat therapy. The article demonstrates the benefits in using the BSD’s advanced synchronous phased array technology for ablation therapy.

The article reviews the evolution of heat therapy for the treatment of cancer and traces the transition of BSD’s patented phased array technology from hyperthermia applications to utilization in BSD’s current ablation therapy technology. The phased array technology and techniques reviewed in the publication were developed by the Company to improve the delivery of heat therapies by directly targeting heating to the tumor. This technology was utilized in the design of the BSD-500 interstitial phased arrays and the BSD-2000 Hyperthermia System to provide uniform preferential heating throughout the central region of a tumor when using two or more antennas.

The Company utilized the same advanced synchronous phased array designs in the development of the MicroThermX Microwave Ablation System (MTX-180) to provide improved targeting of the ablation therapy delivered to the patient (patents pending). These designs allow the MTX-180 to provide larger and more uniform zones of ablation during a single procedure. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market its MicroThermX Microwave Ablation System for ablation of soft tissue.


BSD Medical Receives FDA 510(k) Clearance to Market the MicroThermX Microwave Ablation System

Business Wire  Ag 18, 2010

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market its MicroThermX Microwave Ablation System (MTX-180) for ablation of soft tissue. Clearance from the FDA of BSD’s 510(k) Premarket Notification submission authorizes the commercial sale of the MTX-180 in the United States. The MTX-180 was designed to provide a higher power, optimized system targeted to the growing therapeutic interventional and surgical oncology market.

The MTX-180 utilizes innovative synchronous phased array technology that was developed and patented by BSD to deliver targeted microwave energy to ablate (destroy) soft tissue. BSD employed its extensive 32-year background in developing thermal therapy systems in the design of the MTX-180. BSD’s patented and patents pending technology allows the MTX-180 to provide larger and more uniform zones of ablation during a single procedure. Third party independent testing was conducted at a U.S. university medical center that is a world leader in ablation treatments. The testing data demonstrated that the MTX-180 is a user-friendly system that delivers larger, more uniform ablation zones in shorter periods of time.

The MTX-180 is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MTX-180 is the first of its kind that allows delivery of higher power levels using a single generator. The delivery of microwave energy is controlled utilizing an interactive, touch screen monitor that allows the operator to quickly and easily control the treatment.

“The MTX-180 represents a significant advance in our strategy to diversify BSD’s products and increase revenue,” said Harold Wolcott, BSD President. “The MTX-180 introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2 billion. We believe that the MicroThermX System provides significant advantages over currently available devices that will allow us to capitalize on this rapidly expanding market.”

Currently, radiofrequency (RF) energy is utilized most frequently in the interventional oncology ablation market. Published studies have demonstrated that the use of microwave energy has numerous advantages over RF energy for the delivery of ablation therapy, including faster set-up, shorter ablation times, larger ablation zones, and higher intratumoral temperatures. For these reasons, interventional oncology key opinion leaders regard microwave as the future of soft tissue ablation therapy. The MTX-180 has been designed to provide optimized microwave ablation therapy.

The MTX-180 provides minimally invasive access to the target tissue and can be used in open surgical as well as in percutaneous ablation procedures, which will allow the MTX-180 to be used by both surgeons and interventional radiologists.

CE Marking approval for the MTX-180 System is imminent and will allow BSD to initiate a European market launch.

Disclosure: Long BSDM